[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 2013

Diagnostic Inaccuracy of Smartphone Applications for Melanoma Detection

Author Affiliations

Author Affiliations: Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Drs Akilov, Patton, English, Ho, and Ferris). Mr Wolf and Ms Moreau are medical students at the University of Pittsburgh, Pittsburgh, Pennsylvania.

JAMA Dermatol. 2013;149(4):422-426. doi:10.1001/jamadermatol.2013.2382

Objective To measure the performance of smartphone applications that evaluate photographs of skin lesions and provide the user with feedback about the likelihood of malignancy.

Design Case-control diagnostic accuracy study.

Setting Academic dermatology department.

Participants and Materials Digital clinical images of pigmented cutaneous lesions (60 melanoma and 128 benign control lesions) with a histologic diagnosis rendered by a board-certified dermatopathologist, obtained before biopsy from patients undergoing lesion removal as a part of routine care.

Main Outcome Measures Sensitivity, specificity, and positive and negative predictive values of 4 smartphone applications designed to aid nonclinician users in determining whether their skin lesion is benign or malignant.

Results Sensitivity of the 4 tested applications ranged from 6.8% to 98.1%; specificity, 30.4% to 93.7%; positive predictive value, 33.3% to 42.1%; and negative predictive value, 65.4% to 97.0%. The highest sensitivity for melanoma diagnosis was observed for an application that sends the image directly to a board-certified dermatologist for analysis; the lowest, for applications that use automated algorithms to analyze images.

Conclusions The performance of smartphone applications in assessing melanoma risk is highly variable, and 3 of 4 smartphone applications incorrectly classified 30% or more of melanomas as unconcerning. Reliance on these applications, which are not subject to regulatory oversight, in lieu of medical consultation can delay the diagnosis of melanoma and harm users.